{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T10:49:24Z","timestamp":1777891764747,"version":"3.51.4"},"reference-count":20,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Respir Care"],"published-print":{"date-parts":[[2014,9]]},"abstract":"<jats:sec>\n                    <jats:title>INTRODUCTION:<\/jats:title>\n                    <jats:p>The Cystic Fibrosis Foundation recently deemed the use of extended-interval dosing (EID) of aminoglycosides acceptable for the treatment of cystic fibrosis (CF) pulmonary exacerbations. However, current practice across United States adult CF programs and affiliate programs is unknown. The objectives of this research are to characterize the practice trends, dosing strategies, therapeutic drug-monitoring practices, and adverse effect monitoring of the EID of aminoglycosides in the treatment of pulmonary exacerbations across United States adult CF programs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>A 34-question online survey instrument was distributed on behalf of the author by the United States Cystic Fibrosis Foundation to all United States adult CF programs and affiliate programs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>Of the 68 participating adult CF programs (44.4% survey response rate), 64 (94.1%) reported using EID of aminoglycosides (as once-daily or twice-daily dosing). More than 95% of programs reported frequently or always using this dosing method. Tobramycin dosed 10 mg\/kg\/d every 24 h, infused over 30\u201360 min, was the most commonly cited regimen. Monitoring of aminoglycoside serum concentrations was reported by all programs, with a tobramycin peak of 25\u201330 mg\/L and trough of &lt; 1 mg\/L targeted most frequently. Nephrotoxicity was commonly monitored through serum creatinine measurements, while ototoxicity was monitored by audiometry in approximately one-half of programs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>This study indicates that the use of EID of aminoglycosides across United States adult CF programs has increased considerably since the publication of the CF pulmonary exacerbation guidelines and now appears to be the most common method for dosing aminoglycosides in adults with CF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4187\/respcare.02980","type":"journal-article","created":{"date-parts":[[2014,4,30]],"date-time":"2014-04-30T00:53:43Z","timestamp":1398819223000},"page":"1353-1359","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":25,"title":["A Survey of Extended-Interval Aminoglycoside Dosing Practices in United States Adult Cystic Fibrosis Programs"],"prefix":"10.1177","volume":"59","author":[{"suffix":"Jr","given":"William A","family":"Prescott","sequence":"first","affiliation":[{"name":"University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, New York."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2014,9,1]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.312.7027.338"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/313692"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1995.tb04354.x"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1445-5994.2001.00010.x"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.10036"},{"issue":"31","key":"e_1_3_3_7_2","first-page":"363","article-title":"The influence of the TOPIC study on the prescribing guidelines of aminoglycosides in cystic fibrosis units","volume":"43","author":"Cheong J","year":"2008","unstructured":"Cheong J, , Jacklin A, , Hodson M. The influence of the TOPIC study on the prescribing guidelines of aminoglycosides in cystic fibrosis units. Pediatr Pulmonol, 2008; 43(S31):363.","journal-title":"Pediatr Pulmonol"},{"key":"e_1_3_3_8_2","first-page":"385","article-title":"Prescribing patterns for extended interval aminoglycoside dosing in pediatric patients","volume":"6","author":"Condren M","year":"2001","unstructured":"Condren M, , Luedtke SA. Prescribing patterns for extended interval aminoglycoside dosing in pediatric patients. J Pediatr Pharmacol Ther, 2001; 6:385\u2013391.","journal-title":"J Pediatr Pharmacol Ther"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.20985"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200812-1845PP"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl328"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.1060"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/147.5.918"},{"key":"e_1_3_3_14_2","first-page":"P192","volume-title":"Abstracts of the 24th European Cystic Fibrosis Conference","author":"Riethmueller J","unstructured":"Riethmueller J, , Franke P, , Schroeter TW, , Claass A, , Busch A, , Ziebach R, et al. Optimized intravenous antibiotic treatment with Ceftazidime (thrice daily vs. continuous) and tobramycin (thrice vs. once daily) in CF patients. Abstracts of the 24th European Cystic Fibrosis Conference, June 6\u20139, 2001, Vienna, Austria:P192."},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)17906-9"},{"issue":"1","key":"e_1_3_3_16_2","first-page":"CD002009","article-title":"Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis","author":"Smyth AR","year":"2010","unstructured":"Smyth AR, , Bhatt J. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev, 2010;(1):CD002009.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.78.6.536"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02282885"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.02.00221602"},{"issue":"4","key":"e_1_3_3_20_2","first-page":"262","article-title":"National Survey of Extended-Interval Aminoglycoside Dosing in Pediatric Cystic Fibrosis Pulmonary Exacerbations","volume":"16","author":"Prescott WA","year":"2011","unstructured":"Prescott WA. National Survey of Extended-Interval Aminoglycoside Dosing in Pediatric Cystic Fibrosis Pulmonary Exacerbations. J Pediatr Pharmacol Ther, 2011; 16(4):262\u2013269.","journal-title":"J Pediatr Pharmacol Ther"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1754.2006.00944.x"}],"container-title":["Respiratory Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.4187\/respcare.02980","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.4187\/respcare.02980","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.4187\/respcare.02980","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T06:10:06Z","timestamp":1777615806000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.4187\/respcare.02980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.4187\/respcare.02980"],"URL":"https:\/\/doi.org\/10.4187\/respcare.02980","relation":{},"ISSN":["0020-1324"],"issn-type":[{"value":"0020-1324","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]}}}